8-K: ImmunityBio Secures $75 Million in Registered Direct Offering to Bolster Working Capital

ImmunityBio has entered into a securities purchase agreement for a registered direct offering with a single institutional investor, providing for the issuance of common stock of ImmunityBio as well as warrants for the purchase of additional shares of common stock of ImmunityBio that is expected to result in gross proceeds at closing of approximately $75 million before deducting any offering-related expenses, subject to customary closing conditions.

Summary

• ImmunityBio, Inc. has entered into a securities purchase agreement for a registered direct offering with an institutional investor.
• The offering involves 29,024,768 shares of common stock and warrants to purchase an additional 29,024,768 shares.
• The purchase price is $2.584 per share and accompanying warrant, with an exercise price of $3.101 per share for the warrants.
• The offering is expected to generate gross proceeds of approximately $75 million before deducting offering expenses.
• The warrants are immediately exercisable and expire five years after the issuance date.
• The closing of the offering is expected to occur on or about April 9, 2025, subject to customary closing conditions.
• If fully exercised, the warrants could result in additional gross proceeds of up to approximately $90 million.
• The company intends to use the net proceeds for working capital purposes.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the capital raise is positive for funding operations, it also involves dilution for existing shareholders.

Positives

• The offering provides ImmunityBio with $75 million in gross proceeds to support its business operations.
• The potential exercise of warrants could bring in an additional $90 million.
• The warrants are immediately exercisable, which could provide a quicker influx of capital if exercised promptly.
• The funds will be used for working capital.

Negatives

• The offering involves dilution of existing shareholders' equity.
• The warrants, if exercised, could further dilute shareholders' equity.
• The company is selling shares and warrants at a price below the warrant exercise price.

Risks

• The closing of the offering is subject to customary closing conditions and may not occur as expected.
• The warrants may not be fully exercised, resulting in less than the anticipated $90 million in additional proceeds.
• Forward-looking statements are subject to risks and uncertainties, and actual events may differ materially.
• The company's ability to fund its ongoing and anticipated clinical trials is subject to risks.
• The company's ability to obtain additional financing to fund its operations and complete the development and commercialization of its various product candidates is subject to risks.

Future Outlook

The company anticipates using the proceeds from the offering for working capital and to support ongoing business operations. The potential exercise of warrants could provide additional capital in the future.

Industry Context

Registered direct offerings are a common method for biotechnology companies to raise capital. This offering allows ImmunityBio to secure funding from an institutional investor without a traditional underwritten public offering.

Comparison to Industry Standards

• Comparable companies in the biotechnology sector, such as Sorrento Therapeutics and NantKwest, have also utilized registered direct offerings to raise capital.
• The terms of this offering, including the warrant coverage and exercise price, are within the typical range for similar transactions in the biotech industry.
• The use of proceeds for working capital is a standard practice for biotech companies, which often require significant funding for research and development.

Stakeholder Impact

• Shareholders will experience dilution as a result of the new shares issued.
• The company's employees and operations will benefit from the additional working capital.
• The company's ability to develop and commercialize its product candidates may be enhanced by the funding.

Next Steps

• The company expects to close the offering on or about April 9, 2025, subject to customary closing conditions.
• The company will file a final prospectus supplement with the SEC.
• The company will use the net proceeds from the sale of the Securities hereunder for working capital purposes.

Key Dates

Keywords

registered direct offering, securities purchase agreement, common stock, warrants, equity financing, ImmunityBio, capital raise, working capital, institutional investor, IBRX